METHOD VALIDATION OF RIFAMPICIN ANALYSIS IN HUMAN PLASMA AND ITS APPLICATION IN BIOEQUIVALENCE STUDY
Objective: This research aims to validate the method for rifampicin analysis in plasma by using High-Performance Liquid Chromatography (HPLC) that can be used to study the bioequivalence of a generic tablet of rifampicin 450 mg “X” marketed in Indonesia.
Methods: Bioequivalence test was analysed using HPLC equipped with UV-Vis detector at 377 nm. The mobile phase used was acetonitrile-phosphate buffer pH 6.8 (45:55) delivered at a flow rate of 1.5 ml/min. Bioequivalence test was conducted on a limited number of subjects (n=8). The subjects were divided into two groups randomly. The pharmacokinetic profiles of the test tablet and reference tablet were statistically calculated using SPSS program to see the test tablet and reference tablet were bioequivalence or not.
Results: The developed HPLC method for rifampicin analysis in plasma was sufficiently valid based on the International Conference on Harmonization (ICH) and European Medicines Agency (EMA) guideline, with precision and accuracy values were % Relative Standard Deviation (% RSD = 1.40–13.04) and % Recovery (86.24–102.13), respectively. Meanwhile, the method was linear over studied concentration (0.05 to 10.26 µg/ml) with a coefficient of determination (R2) = 0.9984. The method also had good stability and sensitivity. The result of statistical calculation showed that the generic rifampicin tablet X was bioequivalence toward the reference tablet Rimactan 450 mg.
Conclusion: The test rifampicin tablet that was, the generic tablet “X” was bioequivalence toward the reference rifampicin tablet “Rimactan”.
2. Maggi N, Pasqualucci CR, Ballota R, Sensi P. Rifampicin: A New Orally Active Rifamycin, Chemotherapia 1966;11:285-92.
3. Health Ministry of Republic Indonesia. Tuberkulosis Temukan Obat Sampai Sembuh, Pusat Data dan Informasi Kementrian Kesehatan Republik Indonesia. Jakarta; 2016. p. 2.
4. Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel SS, Back DJ, et al. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 2007;87:248-55.
5. Health Ministry of Republic Indonesia. Formularium Nasional. Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/Menkes/SK/VIII/2013. Jakarta; 2013.
6. Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002;62:2169-83.
7. Panchagnula R and Agrawal S. Biopharmaceutic and Pharmacokinetic Aspects of Variable Bioavailability of Rifampicin. Int J Pharm 2004;27:1-4.
8. Argekar AP, Kunjir SS, Purandare KS. Simultaneous Determination of Rifampicin, Isoniazid and Pyrazinamide by high-performance thin chromatography. J Pharm Biomed Anal 1996;14:1645-50.
9. Hartkoorn RC, Khoo S, Back DJ, Tjia JF, Waitt CJ, Chaponda M, et al. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. J Chromatogr B 2017;857:76-82.
10. Srivastava A, Waterhouse D, Ardrey A, Ward SA. Quantification of rifampicin in human plasma a cerebrospinal fluid by the highly sensitive and rapid chromatographic-tandem mass spectrometric method. J Pharm Biomed Anal 2012;70:523-8.
11. Hee KH, Seo JJ, Lee LS. Development and validation of liquid chromatography-tandem mass spectrometry method for simultaneous quantification of first-line tuberculosis drugs and metabolites in human plasma and its application in the clinical study. J Pharm Biomed Anal 2015;102:253-60.
12. Allanson AL, Cotton MM, Tettey JNA, Boyter AC. Determination of rifampicin in human plasma and blood spots by high-performance liquid chromatography with uv detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal 2007;44:963-9.
13. Van Ewijk Beneken KEWJ, Teulen MJA, van den Hombergh ECA, van Erp NE, Te Brake LHM, Aarnoutse RE. Determination of protein unbound, active rifampicin in serum by ultrafiltration and ultra-performance liquid chromate-graphy with UV detection. A method was suitable for standard and high doses of rifampicin. J Chromatogr B 2017;1063:42-9.
14. The European Medicines Agency. Guideline for good clinical practice E6 (R2). Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2015/08/WC500191488.pdf. [Last accessed on 13 Mar 2019].
15. International Conference on Harmonization. Guidance on Validation of Analytical Procedure Methodology ICH Q2 (R1), Geneva, Switzerland; 2005.
16. Chan CC, Lam H, Lee YC, Zang XM. Analytical method validation and instrument performance verification. Canada: John Wiley and Sons, Inc; 2004. p. 16-24.
17. United States Pharmacopeia and National Formulary. USP-30 NF-25. Asian Edition. Rockville, MD: United States Pharmacopeia Convention; 2007.
18. Sharma S, Goyal S, Chauhan K. A review on analytical method development and validation. Int J Appl Pharm 2018;10:8-15.
19. Snyder LR, Kirkland JJ, Dolan JW. Introduction to modern liquid chromatography. 3th Ed. United States of America: John Wiley and Sons, Inc. Publication; 2010.
20. Ahuja S, Dong MW. Handbook of Pharmaceutical Analysis by HPLC Separation Science and Technology. 1st Ed.: Elsevier; 2005.
21. González AG, Herrador MA, Asuero AG. Intra-laboratory assessment of method accuracy (Trueness and Precision) by using validation standards. Talanta 2010;82:1995-8.
22. Mukti AA, Jannah F, Nurrochmad A, Lukitaningsih E. Development and validation method for quantitative determination of ciprofloxacin in human plasma and its application in bioequivalence test. Asian J Pharm Clin Res 2016;9:89-95.
23. World Medical Association. Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Patients. Edinburgh; 2000.
24. International Conference on Harmonization (ICH) Expert Working Group. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1). Geneva; 1996.
25. Organization for Economic Co-operation and Development (OECD). OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. Number 1. Revised. Paris; 1997.
26. Indonesian Agency of Drug and Food Monitoring. Pedoman Uji Bioekuivalensi. [Indonesian Guideline for Bioequivalence Studies]. Jakarta: BPOM; 2005. Available from: http://jdih.pom.go.id/ showpdf.php?u=89. [Last accessed on 10 Mar 2018].
27. Indonesian Agency of Drug and Food Monitoring. Peraturan Kepala BPOM RI Nomor. HK.03.1.23.12.11.10217. Tentang Obat Wajib Uji Bioequivalensi [BPOM-RIofgulation for Drugs Compulsory for Bioequivalence Studies]. Jakarta: BPOM; 2011. Available from: http://jdih.pom.go.id/showpdf.php?u=97. [Last accessed on 10 Mar 2018.
28. Cruz DD, Babu A, Joshy E, Anesh TP. Bioanalytical method development and validation of ticagrelor by RP-HPLC. Int J Appl Pharm 2017;9:51-4.
29. Shah U, Jasani A. UV spectrophotometric and RP HPLC methods for simultaneous estimation of isoniazid, rifampicin and piperine in the pharmaceutical dosage form. Int J Pharm Pharm Sci 2014;6:273-80.
30. Siddartha TS, Prasanthi B, Santosh T, Ratna JV. Development and validation of high performance liquid chromatographic method for the determination of rifampicin in human plasma. Int J Pharm Pharm Sci 2012;4 Suppl 5:362-7.
This work is licensed under a Creative Commons Attribution 4.0 International License.